This glucose-dependent mechanism of action represents a major therapeutic advantage of GLP-1 receptor agonists, as it substantially reduces the risk of hypoglycemia—a common adverse effect of many traditional antidiabetic agents [8]. This evidence concerns the gene GLP1R and Hypoglycemia.